tradingkey.logo
tradingkey.logo
Pesquisar

Neogenomics Inc

NEO
Adicionar à lista de desejos
14.970USD
+0.380+2.60%
Fechamento 07/01, 16:00ETCotações atrasadas em 15 min
1.95BValor de mercado
PerdaP/L TTM

Mais detalhes de Neogenomics Inc Empresa

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

Informações de Neogenomics Inc

Código da empresaNEO
Nome da EmpresaNeogenomics Inc
Data de listagemDec 10, 2012
CEOZook (Antony P)
Número de funcionários2200
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 10
Endereço9490 Neogenomics Way
CidadeFORT MYERS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33912
Telefone12397680600
Sitehttps://neogenomics.com/
Código da empresaNEO
Data de listagemDec 10, 2012
CEOZook (Antony P)

Executivos da empresa Neogenomics Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jeffrey Scott (Jeff) Sherman
Mr. Jeffrey Scott (Jeff) Sherman
Chief Financial Officer
Chief Financial Officer
220.01K
+0.96%
Mr. Warren Stone
Mr. Warren Stone
President, Chief Operating Officer
President, Chief Operating Officer
164.03K
+3.45%
Mr. Stephen Michael Kanovsky
Mr. Stephen Michael Kanovsky
Independent Director
Independent Director
75.42K
+30.60%
Dr. Neil Gunn
Dr. Neil Gunn
Independent Director
Independent Director
51.18K
+45.09%
Ms. Felicia Williams
Ms. Felicia Williams
Independent Director
Independent Director
30.24K
+76.32%
Ms. Marjorie C. Green
Ms. Marjorie C. Green
Independent Director
Independent Director
22.96K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Michael A. Kelly
Mr. Michael A. Kelly
Lead Independent Director
Lead Independent Director
--
--
Mr. David B. Perez
Mr. David B. Perez
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jeffrey Scott (Jeff) Sherman
Mr. Jeffrey Scott (Jeff) Sherman
Chief Financial Officer
Chief Financial Officer
220.01K
+0.96%
Mr. Warren Stone
Mr. Warren Stone
President, Chief Operating Officer
President, Chief Operating Officer
164.03K
+3.45%
Mr. Stephen Michael Kanovsky
Mr. Stephen Michael Kanovsky
Independent Director
Independent Director
75.42K
+30.60%
Dr. Neil Gunn
Dr. Neil Gunn
Independent Director
Independent Director
51.18K
+45.09%
Ms. Felicia Williams
Ms. Felicia Williams
Independent Director
Independent Director
30.24K
+76.32%
Ms. Marjorie C. Green
Ms. Marjorie C. Green
Independent Director
Independent Director
22.96K
--

Perguntas frequentes

Quem são os cinco principais acionistas de Neogenomics Inc?

Os cinco principais acionistas de Neogenomics Inc são: Mr. Jeffrey Scott (Jeff) Sherman

Quantas instituições possuem ações da Neogenomics Inc (NEO)?

Em 2026Q1, 564 instituições possuíam ações da Neogenomics Inc, com valor de mercado aproximado de 156.61M, representando 120.32% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 7515333.00.

Qual é a maior fonte de receita da Neogenomics Inc?

Em 2026Q1, o segmento de negócios Clinical Services-Client direct billing gerou a maior receita para Neogenomics Inc, totalizando 518.84M e representando 71.34% da receita total.